Summary of project PR001436
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001436. The data can be accessed directly via it's Project DOI: 10.21228/M83Q6B This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR001436 |
| Project DOI: | doi: 10.21228/M83Q6B |
| Project Title: | Quantitative multi-Omics analysis of paclitaxel-loaded Poly(lactide-co-glycolide) nanoparticles for identification of potential biomarkers for head and neck cancer |
| Project Type: | LC-MS/MS |
| Project Summary: | Chemotherapeutic agents are limited by their narrow therapeutic index and high risk for toxicity. The use of nanoparticles (NPs) as carriers for chemotherapeutic agents has considerably increased the therapeutic effect of those drugs by improving their bioavailability and altering their bio-distribution profile. Untargeted metabolomics has emerged as potential approach to understand better tumor progression and treatment outcome of multiple cancer cell types. Herein, we have employed LCMS/MS based untargeted metabolomics to pinpoint differences in metabolic profile of head and neck squamous cell carcinomas FaDu, when treated with anticancer Paclitaxel (PTX) delivered as free drugversus Paclitaxel-loaded poly(lactide-co-glycolide) nanoparticle (PXT-PLGA-NPs). The experimental design include four groups treated with DMSO (control), treated with drug free PXT, PXT-PLGA-NPs and PLGA-NPs without PXT. Data was analyzed using MetaboScape (V4, Bruker Daltonics) platform and matched to Bruker Human Metabolome Data Base (HMDB) spectral library 2.0. We identified and total of 162 high confident assigned metabolites. Principle component analysis of the metabolites revealed that PTX free drug clustered together with PXT-PLGA-NPs, whereas control and PLGA-NPs without PXT clustered away from drug treated cells but apart from each other (see figure below). Further group pairwise comparisons indicated 37 metabolites significantly (p<0.05) dysregulated between PTX free drug and PXT-PLGA-NPs. Of these, it is worthy highlight metabolites that became more abundant with PXT-PLGA-NPs treatment, such as 5-Thymidyclic acid 7. 8 fold change (FC) and 3,4,5-Trimethoxycinnamic acid that have been associated previously associated with effective anticancer drug treatment (Quinn et al. 2015; Anantharaju et al. 2017). The results are in line with our pervious findings supporting a more effective antidrug treatment using NP and we indicate a number of metabolites that are potential markers for monitoring the efficacy antidrug treatment. |
| Institute: | University of Sharjah |
| Department: | Sharjah Institute for Medical Research |
| Laboratory: | Drug Delivery |
| Last Name: | Jagal |
| First Name: | Jayalakshmi |
| Address: | SIMR, Medical Campus, University of Sharjah, 27272, Sharjah |
| Email: | jjagal@sharjah.ac.ae |
| Phone: | +971552863009 |
Summary of all studies in project PR001436
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST002248 | Quantitative multi-Omics analysis of paclitaxel-loaded Poly(lactide-co-glycolide) nanoparticles for identification of potential biomarkers for head and neck cancer | Homo sapiens | University of Sharjah | MS | 2023-07-14 | 1 | 32 | Uploaded data (13.5G)* |
